Cargando…

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET

A bispecific antibody (BsAb) targeting the epidermal growth factor receptor (EGFR) and mesenchymal–epithelial transition factor (MET) pathways represents a novel approach to overcome resistance to targeted therapies in patients with non–small cell lung cancer. In this study, we sequentially screened...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neijssen, Joost, Cardoso, Rosa M.F., Chevalier, Kristen M., Wiegman, Luus, Valerius, Thomas, Anderson, G. Mark, Moores, Sheri L., Schuurman, Janine, Parren, Paul W.H.I., Strohl, William R., Chiu, Mark L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113745/ https://www.ncbi.nlm.nih.gov/pubmed/33839159 http://dx.doi.org/10.1016/j.jbc.2021.100641

Ejemplares similares

Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
por: Grugan, Katharine D., et al.
Publicado: (2016)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel, Danielle, et al.
Publicado: (2021)

Amivantamab治疗EGFR/MET基因异常非小细胞肺癌的单中心经验
Publicado: (2022)

Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody
por: Jarantow, Stephen W., et al.
Publicado: (2015)

Fab-arm exchange: What’s in a name?
por: Schuurman, Janine, et al.
Publicado: (2012)

Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations
por: Petrini, Iacopo, et al.
Publicado: (2022)

The development of amivantamab for the treatment of non-small cell lung cancer
por: Brazel, Danielle, et al.
Publicado: (2023)

Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models
por: Labrijn, Aran F., et al.
Publicado: (2017)

Opening the door to innovation
por: Schuurman, Janine, et al.
Publicado: (2014)

Amivantamab for Metastatic Lung Cancer With Paraneoplastic Disseminated Intravascular Coagulation: A Case Report
por: Ahmad, Yaser, et al.
Publicado: (2023)

Production of stable bispecific IgG1 by controlled Fab-arm exchange: Scalability from bench to large-scale manufacturing by application of standard approaches
por: Gramer, Michael J, et al.
Publicado: (2013)

Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A
por: Zheng, Songmao, et al.
Publicado: (2020)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
por: Olivier, Timothée, et al.
Publicado: (2022)

In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap
por: Rosati, Sara, et al.
Publicado: (2013)

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
por: Engelberts, Patrick J., et al.
Publicado: (2020)

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
por: Middelburg, Jim, et al.
Publicado: (2021)

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies
por: Brahmer, Julie R., et al.
Publicado: (2020)

Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
por: Huang, Lei, et al.
Publicado: (2020)

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
por: Strohl, William R., et al.
Publicado: (2019)

Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity
por: Gammelgaard, Odd L, et al.
Publicado: (2022)

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2021)

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
por: Cho, Byoung Chul, et al.
Publicado: (2023)

Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy
por: Yuan, Qingyun, et al.
Publicado: (2021)

Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
por: Shah, Vishal, et al.
Publicado: (2023)

Avidity in antibody effector functions and biotherapeutic drug design
por: Oostindie, Simone C., et al.
Publicado: (2022)

A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer
por: Sun, Zu-Jun, et al.
Publicado: (2017)

JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis
por: Heinicke, Ulrike, et al.
Publicado: (2015)

Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2022)

A study on the effect of JNJ-10397049 on proliferation and differentiation of neural precursor cells
por: Karami, Neda, et al.
Publicado: (2022)

A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
por: Perez Bay, Andres E., et al.
Publicado: (2023)

Therapeutic antibody engineering: Current and future advances driving the strongest growth area in the pharmaceutical industry
por: Parren, Paul W.H.I., et al.
Publicado: (2013)

The antiviral activity of antibodies in vitro and in vivo
por: Parren, Paul W.H.I., et al.
Publicado: (2001)

Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG
por: Rose, Rebecca J., et al.
Publicado: (2013)

Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma
por: Jiang, Wei, et al.
Publicado: (2021)

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
por: Park, Keunchil, et al.
Publicado: (2021)

Homogeneous Bispecifics by Disulfide Bridging
por: Hull, Elizabeth A., et al.
Publicado: (2014)

Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813
por: Lavreysen, Hilde, et al.
Publicado: (2015)

Drug‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir)
por: Vandenbossche, Joris, et al.
Publicado: (2022)

1958. Antiviral Effects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants With Bronchiolitis, in the Phase 1b Study 53718678RSV1005
por: Martinon-Torres, Federico, et al.
Publicado: (2018)

Clinical evaluation of [(18)F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer’s disease
por: Schmidt, Mark E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7h1091qh2d6mqodo6m9jgtfq7b